Common use of Audit Dispute Clause in Contracts

Audit Dispute. In the event of a dispute with respect to any audit under Section 8.13, AstraZeneca and Mereo shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***] days, the dispute shall be submitted for resolution to one (1) of the big four (4) public accounting firms, jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Auditor”). The decision of the Auditor shall be final and the costs of such arbitration as well as the initial audit shall be borne between the Parties in such manner as the Auditor shall determine. Not later than [***] days after such decision and in accordance with such decision, Mereo shall pay the additional amounts or AstraZeneca shall reimburse the excess payments, as applicable.

Appears in 4 contracts

Sources: Exclusive License and Option Agreement, Exclusive License and Option Agreement (Mereo Biopharma Group PLC), Exclusive License and Option Agreement (Mereo Biopharma Group PLC)

Audit Dispute. In the event of a dispute with respect to any audit under Section 8.134.11, AstraZeneca and Mereo Licensee shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***] days([***]) [***], the dispute shall be submitted for resolution to one (1) of the big four (4) a certified public accounting firms, firm jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the "Auditor"). The decision of the Auditor shall be final and the costs of such arbitration as well as the initial audit shall be borne between the Parties in such manner as the Auditor shall determine. Not later than [***] days ([***]) [***] after such decision and in accordance with such decision, Mereo Licensee shall pay the additional amounts amounts, with interest from the date originally due as provided in Section 4.9 or AstraZeneca shall reimburse the excess payments, as applicable.

Appears in 2 contracts

Sources: License Agreement (Biohaven Research Ltd.), License Agreement (Biohaven Pharmaceutical Holding Co Ltd.)

Audit Dispute. In the event of a dispute with respect to any audit under Section 8.13, AstraZeneca and Mereo ▇▇▇▇▇ shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***] days, the dispute shall be submitted for resolution to one (1) of the big four (4) public accounting firms, jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Auditor”). The decision of the Auditor shall be final and the costs of such arbitration as well as the initial audit shall be borne between the Parties in such manner as the Auditor shall determine. Not later than [***] days after such decision and in accordance with such decision, Mereo shall pay the additional amounts or AstraZeneca shall reimburse the excess payments, as applicable.

Appears in 1 contract

Sources: Amendment and Restatement Agreement (Mereo BioPharma Group PLC)

Audit Dispute. In the event of a dispute with respect to any audit under Section 8.13clause 5.10(b), AstraZeneca Heptares and Mereo Neurocrine shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***] days, the dispute shall be submitted for resolution to one (1) of the big four (4) a certified public accounting firms, firm jointly selected by each Party’s certified public accountants or to such other Person person as the Parties shall mutually agree (the "Dispute Auditor"). The decision of the Dispute Auditor shall be final and the costs of such arbitration dispute resolution as well as the initial audit shall be borne between the Parties in such manner as the Auditor shall determine. Not later than [***] days after such decision and in accordance with such decision, Mereo the Parties shall pay the additional amounts or AstraZeneca shall reimburse the excess payments, make reconciling payments as applicabledescribed in Section 5.10(c).

Appears in 1 contract

Sources: Collaboration and License Agreement (Neurocrine Biosciences Inc)